Page last updated: 2024-10-18

dihydroxyphenylalanine and Lupus Erythematosus, Systemic

dihydroxyphenylalanine has been researched along with Lupus Erythematosus, Systemic in 1 studies

Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.
dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.

Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Klawans, HL1

Reviews

1 review available for dihydroxyphenylalanine and Lupus Erythematosus, Systemic

ArticleYear
The pharmacology of extrapyramidal movement disorders.
    Monographs in neural sciences, 1973, Volume: 2

    Topics: Basal Ganglia Diseases; Chorea; Dihydroxyphenylalanine; Dopamine; Dystonia Musculorum Deformans; Hep

1973